Radiomics for Prediction of Long Term Survival and Local Failure After Stereotactic Radiotherapy for Brain Metastases

Value of Radiomics for the Prediction of Long Term Survival and Local Failure After Stereotactic Radiotherapy (SRT) for Brain Metastases

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02265549

Enrollment

155

Registered

2014-10-16

Start date

2014-05-31

Completion date

2014-09-04

Last updated

2018-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastases, Neoplasm

Keywords

Metastases,, Neoplasm, Cerebral

Brief summary

Published prognostic scores have limitations in prediction of long term survival after stereotactic radiotherapy for brain metastases. Moreover, no validated tools are available for prediction of local failure. The value of radiomics is evaluated in this perspective.

Detailed description

Sensitivity is low for prediction of long term survival of currently available prognostic scores for brain metastases. First the current clinical models will be optimized with a new prognostic model and nomogram. Radiomics is a tool to analyze tumor characteristics based on CT and MR images. These tumor characteristics may reflect tumor biology and outcome. Therefore it is investigated if radiomics improves prediction of long term survival after stereotactic radiotherapy for brain metastases. Moreover, the predictive value of radiomics for local failure is investigated.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Cerebral metastasized patients

Exclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
Sensitive value of 12 months survival after stereotactic radiotherapy for brain metastases with radiomics	1 year	Sensitivity of 12 months survival after stereotactic radiotherapy for brain metastases with radiomics. Radiomics is a tool to analyze tumor characteristics based on CT and MR images.
Sensitive value of 12 months local failure after stereotactic radiotherapy for brain metastases with radiomics	1 year	Sensitivity of 12 months local failure after stereotactic radiotherapy for brain metastases with radiomics. Radiomics is a tool to analyze tumor characteristics based on CT and MR images.

Secondary

Measure	Time frame	Description
Negative predictive value of 12 months survival and local failure after stereotactic radiotherapy for brain metastases with radiomics.	1 year	Negative predictive value of 12 months survival and local failure after stereotactic radiotherapy for brain metastases with radiomics.
Positive predictive value of 12 months survival and local failure after stereotactic radiotherapy for brain metastases with radiomics.	1 year	Positive predictive value of 12 months survival and local failure after stereotactic radiotherapy for brain metastases with radiomics.
Specificity of 12 months survival and local failure after stereotactic radiotherapy for brain metastases with radiomics.	1 year	Specificity of 12 months survival and local failure after stereotactic radiotherapy for brain metastases with radiomics.

Other

Measure	Time frame	Description
Area under the curve of published prognostic scores	1 year	Area under the curve published prognostic scores
Mismatch rate of published prognostic scores	1 year	Mismatch rate of published prognostic scores

Countries

Netherlands

Outcome results